Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on September 3, 2026, disclosing the sale of 5,327 shares of common stock on September 2, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units.

Key Highlights

  • Reporting person: Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc.
  • Transaction date: September 2, 2026
  • Shares sold: 5,327 shares of common stock, disposed of (transaction code S)
  • Weighted average sale price: $19.1131 per share, with individual prices ranging from $18.89 to $19.545
  • Purpose of sale: To cover tax withholding obligations associated with the vesting of restricted stock units, according to the filing
  • Beneficial ownership following transaction: 124,027 shares of common stock held directly

Hopman RSU Vesting Triggers Tax-Related Share Sale at Beta Bionics

According to the Form 4 filed with the Securities and Exchange Commission on September 3, 2026, Mark Hopman, serving as Chief Commercial Officer at Beta Bionics, Inc., disposed of 5,327 shares of common stock on September 2, 2026. The filing states that "the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units," identifying the sale as a tax-driven transaction rather than an open-market discretionary sale.

The filing reports a weighted average sale price of $19.1131 per share. It further notes that the prices in the transaction ranged between $18.89 and $19.545, and that "full information regarding the number of shares sold at each separate price will be provided" upon request by the SEC staff, the issuer, or any security holder of the issuer. Following the reported transaction, Hopman's direct beneficial ownership in Beta Bionics common stock stands at 124,027 shares, according to the filing.

The Form 4 was signed by Stephen Feider as Attorney-in-Fact on behalf of Hopman and submitted on September 3, 2026. No derivative securities transactions were reported in Table II of the filing. The filing was made by one reporting person and does not indicate any amendment to a prior filing.

What Was Disclosed

Beta Bionics Chief Commercial Officer Mark Hopman reported a sale of 5,327 common shares on September 2, 2026, at a weighted average price of $19.1131, solely to satisfy tax obligations from vesting restricted stock units, leaving him with 124,027 shares directly held.